NYSEAMERICAN:LCTX Lineage Cell Therapeutics (LCTX) Stock Price, News & Analysis $1.30 0.00 (0.00%) Closing price 05/22/2026 04:10 PM EasternExtended Trading$1.30 -0.01 (-0.38%) As of 05/22/2026 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock About Lineage Cell Therapeutics Stock (NYSEAMERICAN:LCTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LCTX alerts:Sign Up Key Stats Today's Range$1.28▼$1.3750-Day Range$1.20▼$1.7152-Week Range$0.60▼$2.09Volume788,031 shsAverage Volume1.45 million shsMarket Capitalization$324.09 millionP/E RatioN/ADividend YieldN/APrice Target$6.25Consensus RatingBuy Company Overview Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations. Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration. In parallel, Lineage is advancing oligodendrocyte progenitor cell therapies for spinal cord injury and conducting early-stage programs in immune-effector cell oncology, including dendritic cell-based vaccines and natural killer-cell products intended to stimulate or enhance anti-tumor responses. Founded in the 1990s as BioTime and rebranded in late 2019, Lineage Cell Therapeutics is headquartered in Carlsbad, California, with research and development activities extending into clinical sites across the United States and Europe. The company’s leadership team is led by President and Chief Executive Officer Brian Culley, supported by an experienced scientific advisory board. Through its integrated development strategy, Lineage aims to translate stem cell science into scalable therapies that address significant unmet medical needs in ophthalmology, neurology and oncology.AI Generated. May Contain Errors. Read More Lineage Cell Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreLCTX MarketRank™: Lineage Cell Therapeutics scored higher than 59% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingBuy Consensus RatingLineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and no sell ratings.Upside PotentialLineage Cell Therapeutics has a consensus price target of $6.25, representing about 380.8% upside from its current price of $1.30.Amount of Analyst CoverageLineage Cell Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Lineage Cell Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lineage Cell Therapeutics are expected to grow in the coming year, from ($0.07) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lineage Cell Therapeutics is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lineage Cell Therapeutics is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLineage Cell Therapeutics has a P/B Ratio of 6.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lineage Cell Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.63% of the float of Lineage Cell Therapeutics has been sold short.Short Interest Ratio / Days to CoverLineage Cell Therapeutics has a short interest ratio ("days to cover") of 21.73, which indicates bearish sentiment.Change versus previous monthShort interest in Lineage Cell Therapeutics has recently increased by 1.15%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLineage Cell Therapeutics does not currently pay a dividend.Dividend GrowthLineage Cell Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest13 people have searched for LCTX on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.MarketBeat Follows4 people have added Lineage Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $24,300.00 in company stock, which represents 0.0075% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Lineage Cell Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $24,300.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders24.70% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.47% of the stock of Lineage Cell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lineage Cell Therapeutics' insider trading history. Receive LCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LCTX Stock News HeadlinesLineage Cell Therapeutics (LCTX) price target increased by 14.58% to 5.61May 14, 2026 | msn.comLineage Cell Therapeutics Inc (LCTX) Q1 2026 Earnings Call Highlights: Strategic Advances and ...May 13, 2026 | finance.yahoo.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2026 Earnings Call TranscriptMay 13, 2026 | insidermonkey.comLineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comLineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | businesswire.comLineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026May 5, 2026 | businesswire.comCanaccord Genuity initiates coverage of Lineage Cell Therapeutics (LCTX) with buy recommendationApril 29, 2026 | msn.comSee More Headlines LCTX Stock Analysis - Frequently Asked Questions How have LCTX shares performed this year? Lineage Cell Therapeutics' stock was trading at $1.67 at the start of the year. Since then, LCTX stock has decreased by 22.2% and is now trading at $1.30. How were Lineage Cell Therapeutics' earnings last quarter? Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) issued its earnings results on Tuesday, May, 12th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.01. The firm had revenue of $1.73 million for the quarter, compared to analysts' expectations of $3.60 million. Lineage Cell Therapeutics had a negative net margin of 434.44% and a negative trailing twelve-month return on equity of 89.36%. Read the conference call transcript. Who are Lineage Cell Therapeutics' major shareholders? Lineage Cell Therapeutics' top institutional shareholders include Fifth Third Bancorp (1.85%), Renaissance Technologies LLC (0.85%), Sei Investments Co. (0.17%) and Bank of America Corp DE (0.17%). Insiders that own company stock include Broadwood Partners, LP, Brian M Culley, Don M Bailey and Jill Ann Howe. View institutional ownership trends. How do I buy shares of Lineage Cell Therapeutics? Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lineage Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lineage Cell Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Moderna (MRNA), JPMorgan Chase & Co. (JPM) and Chevron (CVX). Company Calendar Last Earnings5/12/2026Today5/25/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 6 days, LCTX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:LCTX CIK876343 Webwww.lineagecell.com Phone(442) 287-8963Fax510-521-3389Employees60Year FoundedN/APrice Target and Rating Average Price Target for Lineage Cell Therapeutics$6.25 High Price Target$9.00 Low Price Target$3.00 Potential Upside/Downside+380.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.53 million Net Margins-434.44% Pretax Margin-468.86% Return on Equity-89.36% Return on Assets-36.39% Debt Debt-to-Equity RatioN/A Current Ratio6.89 Quick Ratio6.89 Sales & Book Value Annual Sales$14.56 million Price / Sales22.26 Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book6.19Miscellaneous Outstanding Shares249,300,000Free Float187,721,000Market Cap$324.09 million OptionableNot Optionable Beta1.60 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NYSEAMERICAN:LCTX) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredTrump Admin to Pump $1 Billion into this “Off-the-Radar” AI StockThe U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...InvestorPlace | SponsoredThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...Behind the Markets | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredGold surged 600 dollars last time this indicator peakedThe Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lineage Cell Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lineage Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
